Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.23|
|52 Week High||AU$0.19|
|52 Week Low||AU$0.46|
|1 Month Change||-12.96%|
|3 Month Change||-18.97%|
|1 Year Change||14.63%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||0%|
Recent News & Updates
We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|NYR||AU Pharmaceuticals||AU Market|
Return vs Industry: NYR exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: NYR underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: NYR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: NYR's weekly volatility (8%) has been stable over the past year.
About the Company
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in the drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; NYR-BI01, a neuroprotectant drug, to reduce the disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company has collaboration with Walter Reed Army Institute of Research and University of New South Wales, Sydney for advancement of preclinical neuroprotection compound for traumatic brain injury.
Nyrada Fundamentals Summary
|NYR fundamental statistics|
Is NYR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NYR income statement (TTM)|
|Cost of Revenue||AU$2.18m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.029|
|Net Profit Margin||-151.51%|
How did NYR perform over the long term?See historical performance and comparison
Is Nyrada undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NYR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NYR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NYR is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: NYR is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NYR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NYR is good value based on its PB Ratio (2x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Nyrada forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nyrada has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Nyrada performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: NYR is currently unprofitable.
Growing Profit Margin: NYR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NYR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NYR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NYR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: NYR has a negative Return on Equity (-24.42%), as it is currently unprofitable.
How is Nyrada's financial position?
Financial Position Analysis
Short Term Liabilities: NYR's short term assets (A$15.1M) exceed its short term liabilities (A$665.4K).
Long Term Liabilities: NYR has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NYR is debt free.
Reducing Debt: NYR had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NYR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NYR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 29.5% each year
What is Nyrada current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NYR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NYR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NYR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NYR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NYR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. James Bonnar has been Chief Executive Officer of Nyrada Inc. Mr. Bonnar had been Vice-President of R&D at Nyrada Inc. since February 2018. He joined Nyrada in February 2018, bringing over 20 years of e...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD280.59K) is about average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Experienced Board: NYR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.4%.
Nyrada Inc.'s employee growth, exchange listings and data sources
- Name: Nyrada Inc.
- Ticker: NYR
- Exchange: ASX
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$28.882m
- Shares outstanding: 122.90m
- Website: https://www.nyrada.com
- Nyrada Inc.
- 828 Pacific Highway
- Suite 2
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:38|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.